Progress Toward an Integrated Understanding of Parkinson's Disease

Overview

Journal F1000Res

Specialties Biomedical Engineering
Science

Date 2017 Jul 29

PMID 28751973

Citations 13

Authors

Maxime W C Rousseaux

Joshua M Shulman

Joseph Jankovic

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, affecting over 10 million individuals worldwide. While numerous effective symptomatic treatments are currently available, no curative or disease-modifying therapies exist. An integrated, comprehensive understanding of PD pathogenic mechanisms will likely address this unmet clinical need. Here, we highlight recent progress in PD research with an emphasis on promising translational findings, including (i) advances in our understanding of disease susceptibility, (ii) improved knowledge of cellular dysfunction, and (iii) insights into mechanisms of spread and propagation of PD pathology. We emphasize connections between these previously disparate strands of PD research and the development of an emerging systems-level understanding that will enable the next generation of PD therapeutics.

Citing Articles

Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy.

Parmasad J, Ricke K, Nguyen B, Stykel M, Buchner-Duby B, Bruce A Cell Death Dis. 2024; 15(4):246.

PMID: 38575601 PMC: 10994937. DOI: 10.1038/s41419-024-06534-8.

An investigation of the contribution of different turn speeds during standing turns in individuals with and without Parkinson's disease.

Khobkhun F, Pereira Santiago P, Tahara A, Srivanitchapoom P, Richards J Sci Rep. 2022; 12(1):22566.

PMID: 36581700 PMC: 9800358. DOI: 10.1038/s41598-022-27217-4.

Transcranial Direct Current Stimulation on Parkinson's Disease: Systematic Review and Meta-Analysis.

de Oliveira P, Araujo T, da Silva Machado D, Rodrigues A, Bikson M, Andrade S Front Neurol. 2022; 12:794784.

PMID: 35082749 PMC: 8785799. DOI: 10.3389/fneur.2021.794784.

Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers.

Bitencourt A, Campos R, Cline E, Klein W, Sebollela A Int J Mol Sci. 2020; 21(23).

PMID: 33255488 PMC: 7727795. DOI: 10.3390/ijms21238920.

Epigenetic Basis of Lead-Induced Neurological Disorders.

Wang T, Zhang J, Xu Y Int J Environ Res Public Health. 2020; 17(13).

PMID: 32645824 PMC: 7370007. DOI: 10.3390/ijerph17134878.

References

. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol. 2011; 95(4):629-35. PMC: 9014725. DOI: 10.1016/j.pneurobio.2011.09.005. View

Jansen I, Ye H, Heetveld S, Lechler M, Michels H, Seinstra R . Discovery and functional prioritization of Parkinson's disease candidate genes from large-scale whole exome sequencing. Genome Biol. 2017; 18(1):22. PMC: 5282828. DOI: 10.1186/s13059-017-1147-9. View

Valenca G, Srivastava G, Oliveira-Filho J, White C, Yu L, Schneider J . The Role of MAPT Haplotype H2 and Isoform 1N/4R in Parkinsonism of Older Adults. PLoS One. 2016; 11(7):e0157452. PMC: 4961370. DOI: 10.1371/journal.pone.0157452. View

Migdalska-Richards A, Ko W, Li Q, Bezard E, Schapira A . Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Synapse. 2017; 71(7). PMC: 5485051. DOI: 10.1002/syn.21967. View

Davis M, Johnson C, Leverenz J, Weintraub D, Trojanowski J, Chen-Plotkin A . Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurol. 2016; 73(10):1217-1224. PMC: 5056861. DOI: 10.1001/jamaneurol.2016.2245. View

Lotia M, Jankovic J . New and emerging medical therapies in Parkinson's disease. Expert Opin Pharmacother. 2016; 17(7):895-909. DOI: 10.1517/14656566.2016.1149163. View

Luk K, Song C, OBrien P, Stieber A, Branch J, Brunden K . Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A. 2009; 106(47):20051-6. PMC: 2785290. DOI: 10.1073/pnas.0908005106. View

Sampson T, Debelius J, Thron T, Janssen S, Shastri G, Ilhan Z . Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. Cell. 2016; 167(6):1469-1480.e12. PMC: 5718049. DOI: 10.1016/j.cell.2016.11.018. View

Singleton A . A new gene for Parkinson's disease: should we care?. Lancet Neurol. 2015; 14(3):238-9. DOI: 10.1016/S1474-4422(14)70270-4. View

10.

Haelterman N, Yoon W, Sandoval H, Jaiswal M, Shulman J, Bellen H . A mitocentric view of Parkinson's disease. Annu Rev Neurosci. 2014; 37:137-59. PMC: 4659514. DOI: 10.1146/annurev-neuro-071013-014317. View

11.

Mata I, Leverenz J, Weintraub D, Trojanowski J, Chen-Plotkin A, Van Deerlin V . GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord. 2015; 31(1):95-102. PMC: 4724255. DOI: 10.1002/mds.26359. View

12.

Chartier-Harlin M, Dachsel J, Vilarino-Guell C, Lincoln S, Lepretre F, Hulihan M . Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet. 2011; 89(3):398-406. PMC: 3169825. DOI: 10.1016/j.ajhg.2011.08.009. View

13.

Andres-Mateos E, Perier C, Zhang L, Blanchard-Fillion B, Greco T, Thomas B . DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A. 2007; 104(37):14807-12. PMC: 1976193. DOI: 10.1073/pnas.0703219104. View

14.

McCann H, Cartwright H, Halliday G . Neuropathology of α-synuclein propagation and braak hypothesis. Mov Disord. 2015; 31(2):152-60. DOI: 10.1002/mds.26421. View

15.

Mecozzi V, Berman D, Simoes S, Vetanovetz C, Awal M, Patel V . Pharmacological chaperones stabilize retromer to limit APP processing. Nat Chem Biol. 2014; 10(6):443-9. PMC: 4076047. DOI: 10.1038/nchembio.1508. View

16.

Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, Kimura M . Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature. 2014; 510(7503):162-6. DOI: 10.1038/nature13392. View

17.

Schon E, Manfredi G . Neuronal degeneration and mitochondrial dysfunction. J Clin Invest. 2003; 111(3):303-12. PMC: 151870. DOI: 10.1172/JCI17741. View

18.

Tarakad A, Jankovic J . Diagnosis and Management of Parkinson's Disease. Semin Neurol. 2017; 37(2):118-126. DOI: 10.1055/s-0037-1601888. View

19.

Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M . α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015; 522(7556):340-4. DOI: 10.1038/nature14547. View

20.

George S, Brundin P . Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation. J Parkinsons Dis. 2015; 5(3):413-24. PMC: 4923719. DOI: 10.3233/JPD-150630. View